Human Milk Oligosaccharides Market Size, Share & Industry Analysis, By Type , By Application (Dairy, Bakery, Dietary Supplements, Infant Formula, Beverages) and Regional Forecast, 2024-2032

The global human milk oligosaccharides market size is expected to experience substantial growth in the foreseeable future. This information is published by Fortune Business Insights™ in its report titled "Human Milk Oligosaccharides Market, 2024-2032". Human milk oligosaccharides (HMO), is a conjugated complex carbohydrate that is the third most abundant component in the human milk. HMOs are the growing substrate for the good bacteria present in the gut and help to improve digestion in the babies. Thus, they are extensively used as an ingredient in the infant formula. They are also consumed as prebiotics for gut health improvement. Owing to all these benefits, the demand for HMOs is growing.

The growing health conscious among consumers has led to the utilization of HMO as a nutritional ingredient in various functional food and beverages. Moreover, the availability of new technologies such as enzymatic transglycosylation technique to artificially synthesize HMOs has further boosted its market growth.

The increasing awareness among the consumers about the maintenance of gut microbiota in infants and toddlers for their health and development is a major factor driving the market growth.

The high price of the HMO containing products due to the use of costly synthesizing methods is a major restraint in the market growth. Further, the availability of alternative human milk oligosaccharides that have the same functional benefits have also impeded its market growth.

Key Players Covered:

• BASF SE


• Jennewein Biotechnologie GmbH


• Glycom A/S, Inbiose


• Glycosyn


• zuChem, Inc.


• Elicityl SA


• Nestlé S.A.


• DuPont de Nemours, Inc.


• Royal FrieslandCampina N.V.

SEGMENTATION:

The global human milk oligosaccharides market is segmented by type and application. The 2’FL HMO is holding the major market share as it is commonly found HMO in human milk. Also, the 2’FL variant is widely preferred for formulating infant formulas and dietary supplements.

The infant formula segment is holding the largest share in the market. This is due to the significant rise in the infant fatality rate followed by the increasing concerns of the parents regarding the health and safety of their infants. In addition to these factors, HMOs help in keeping gastrointestinal diseases at bay.

Regional Analysis:

North America reported to hold significant share in the HMO market due to the increase in consumption of functional food and beverages. The incorporation of HMOs in various food and beverages as a functional ingredient to boost the gut health and overall immunity has boosted its regional market growth.

Asia Pacific is expected to hold a significant market share in the upcoming years, due to thegrowth in infant formula sector. Many prominent players are establishing their production base in the emerging economies, such as China and India. Further, the increase in disposable income of the consumers allows them to pay premium prices for such products, which in turn aids the regional sales performance of HMO.

Europe is witnessing a significant growth in the market owing to the rise in consumption of dietary supplements, especially by the geriatric population. Italy, France and Germany are among the highest consumers of dietary supplements. Further, the growing nutraceuticals sector stokes it’s the demand for HMO in the region.

HUMAN MILK OLIGOSACCHARIDES MARKET SEGMENTATION ANALYSIS:

Key Industry Developments

• In October 2019, BASF SE launched Prebilac, a human milk oligosaccharide 2’FL ingredient as a “new hot thing”. This product was developed in partnership with a biotechnology firm Glycosyn, to enhances BASF’s product portfolio beyond infant nutrition.


• In July 2017, Nestle Spain launched a new infant formula that reproduces two human milk oligosaccharides. The ingredients are approved by both the European Food Safety Authority and the US Food and Drug Administration